Cargando…

Level of inflammatory cytokines tumour necrosis factor α, interleukins 12, 23 and 17 in patients with psoriasis in the context of metabolic syndrome

INTRODUCTION: Psoriasis is a chronic inflammatory skin disease with immunologic etiology. AIM: To investigate the levels of the proinflammatory cytokines tumor necrosis factor α (TNF-α), interleukin 23 (IL-23) and IL-17 in patients with psoriasis and psoriatic arthritis with concomitant metabolic sy...

Descripción completa

Detalles Bibliográficos
Autores principales: Pirowska, Magdalena, Podolec, Katarzyna, Lipko-Godlewska, Sylwia, Sułowicz, Joanna, Brzewski, Paweł, Obtułowicz, Aleksander, Pastuszczak, Maciej, Wojas-Pelc, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409868/
https://www.ncbi.nlm.nih.gov/pubmed/30858782
http://dx.doi.org/10.5114/ada.2018.73136
_version_ 1783402090776756224
author Pirowska, Magdalena
Podolec, Katarzyna
Lipko-Godlewska, Sylwia
Sułowicz, Joanna
Brzewski, Paweł
Obtułowicz, Aleksander
Pastuszczak, Maciej
Wojas-Pelc, Anna
author_facet Pirowska, Magdalena
Podolec, Katarzyna
Lipko-Godlewska, Sylwia
Sułowicz, Joanna
Brzewski, Paweł
Obtułowicz, Aleksander
Pastuszczak, Maciej
Wojas-Pelc, Anna
author_sort Pirowska, Magdalena
collection PubMed
description INTRODUCTION: Psoriasis is a chronic inflammatory skin disease with immunologic etiology. AIM: To investigate the levels of the proinflammatory cytokines tumor necrosis factor α (TNF-α), interleukin 23 (IL-23) and IL-17 in patients with psoriasis and psoriatic arthritis with concomitant metabolic syndrome. MATERIAL AND METHODS: This study included 60 patients with severe psoriasis. RESULTS: In patients with arterial hypertension concomitant with psoriasis, no statistically significant differences in cytokine levels were observed. On the other hand, in the group of patients diagnosed with diabetes, an increased level of IL-17 was observed. In patients with lipid disorders, the results were similar to the results of patients with diabetes. CONCLUSIONS: It is very important to study immunologic mechanisms responsible for the presence and severity of psoriasis, in order to personalize the therapy in the future and optimize the effect of action on the basic disease and on concomitant disorders.
format Online
Article
Text
id pubmed-6409868
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-64098682019-03-11 Level of inflammatory cytokines tumour necrosis factor α, interleukins 12, 23 and 17 in patients with psoriasis in the context of metabolic syndrome Pirowska, Magdalena Podolec, Katarzyna Lipko-Godlewska, Sylwia Sułowicz, Joanna Brzewski, Paweł Obtułowicz, Aleksander Pastuszczak, Maciej Wojas-Pelc, Anna Postepy Dermatol Alergol Original Paper INTRODUCTION: Psoriasis is a chronic inflammatory skin disease with immunologic etiology. AIM: To investigate the levels of the proinflammatory cytokines tumor necrosis factor α (TNF-α), interleukin 23 (IL-23) and IL-17 in patients with psoriasis and psoriatic arthritis with concomitant metabolic syndrome. MATERIAL AND METHODS: This study included 60 patients with severe psoriasis. RESULTS: In patients with arterial hypertension concomitant with psoriasis, no statistically significant differences in cytokine levels were observed. On the other hand, in the group of patients diagnosed with diabetes, an increased level of IL-17 was observed. In patients with lipid disorders, the results were similar to the results of patients with diabetes. CONCLUSIONS: It is very important to study immunologic mechanisms responsible for the presence and severity of psoriasis, in order to personalize the therapy in the future and optimize the effect of action on the basic disease and on concomitant disorders. Termedia Publishing House 2019-02-02 2019-02 /pmc/articles/PMC6409868/ /pubmed/30858782 http://dx.doi.org/10.5114/ada.2018.73136 Text en Copyright: © 2019 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Original Paper
Pirowska, Magdalena
Podolec, Katarzyna
Lipko-Godlewska, Sylwia
Sułowicz, Joanna
Brzewski, Paweł
Obtułowicz, Aleksander
Pastuszczak, Maciej
Wojas-Pelc, Anna
Level of inflammatory cytokines tumour necrosis factor α, interleukins 12, 23 and 17 in patients with psoriasis in the context of metabolic syndrome
title Level of inflammatory cytokines tumour necrosis factor α, interleukins 12, 23 and 17 in patients with psoriasis in the context of metabolic syndrome
title_full Level of inflammatory cytokines tumour necrosis factor α, interleukins 12, 23 and 17 in patients with psoriasis in the context of metabolic syndrome
title_fullStr Level of inflammatory cytokines tumour necrosis factor α, interleukins 12, 23 and 17 in patients with psoriasis in the context of metabolic syndrome
title_full_unstemmed Level of inflammatory cytokines tumour necrosis factor α, interleukins 12, 23 and 17 in patients with psoriasis in the context of metabolic syndrome
title_short Level of inflammatory cytokines tumour necrosis factor α, interleukins 12, 23 and 17 in patients with psoriasis in the context of metabolic syndrome
title_sort level of inflammatory cytokines tumour necrosis factor α, interleukins 12, 23 and 17 in patients with psoriasis in the context of metabolic syndrome
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409868/
https://www.ncbi.nlm.nih.gov/pubmed/30858782
http://dx.doi.org/10.5114/ada.2018.73136
work_keys_str_mv AT pirowskamagdalena levelofinflammatorycytokinestumournecrosisfactorainterleukins1223and17inpatientswithpsoriasisinthecontextofmetabolicsyndrome
AT podoleckatarzyna levelofinflammatorycytokinestumournecrosisfactorainterleukins1223and17inpatientswithpsoriasisinthecontextofmetabolicsyndrome
AT lipkogodlewskasylwia levelofinflammatorycytokinestumournecrosisfactorainterleukins1223and17inpatientswithpsoriasisinthecontextofmetabolicsyndrome
AT sułowiczjoanna levelofinflammatorycytokinestumournecrosisfactorainterleukins1223and17inpatientswithpsoriasisinthecontextofmetabolicsyndrome
AT brzewskipaweł levelofinflammatorycytokinestumournecrosisfactorainterleukins1223and17inpatientswithpsoriasisinthecontextofmetabolicsyndrome
AT obtułowiczaleksander levelofinflammatorycytokinestumournecrosisfactorainterleukins1223and17inpatientswithpsoriasisinthecontextofmetabolicsyndrome
AT pastuszczakmaciej levelofinflammatorycytokinestumournecrosisfactorainterleukins1223and17inpatientswithpsoriasisinthecontextofmetabolicsyndrome
AT wojaspelcanna levelofinflammatorycytokinestumournecrosisfactorainterleukins1223and17inpatientswithpsoriasisinthecontextofmetabolicsyndrome